Joanna Horobin

Biography

Dr. Horobin joined the company as Senior Vice President and Chief Medical Officer in November 2015. Prior to joining Idera, Dr. Horobin was most recently the Chief Medical Officer of Verastem,Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals. Additionally, Dr.Horobin held several roles of increasing responsibility at global pharmaceutical corporations suchas Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the global Oncology business unit’slaunch which included the launches of Taxotere® (docetaxel) in breast cancer andCampto/Camptosar® (CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venturewith Chugai to launch Granocyte® (lenograstim). Prior, Dr. Horobin played significant leadershiproles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® andRelafen®/Reliflex®. Dr. Horobin received her medical degree from the University of Manchester,England. 

Research Interest

company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA.